A Surprising Link Between Shingles and Dementia

Dementia, a devastating neurological disorder characterized by memory loss, cognitive decline, and behavioral changes, poses a significant health challenge, especially in the UK. With its prevalence skyrocketing, the need for effective preventive measures has never been more critical. Yet, the complexity of dementia’s causes makes finding solutions particularly daunting.

Breakthrough Research Uncovers New Hope

In an exciting development, a groundbreaking study by Maxine Taquet and her team, published in *Nature Medicine* in June 2024, reveals an unanticipated benefit of the shingles vaccine: it may lower the risk of developing dementia. The varicella-zoster virus (VZV), responsible for shingles, is known to cause inflammation and damage to the brain's neural pathways. This damage could potentially lead to neurodegenerative processes that exacerbate dementia, affecting the brain's blood vessels and triggering harmful inflammatory responses.

Study Findings That Could Change the Game

Using comprehensive data from US electronic health records, Taquet's research exploited a unique opportunity created by the widespread adoption of the recombinant shingles vaccine and the phased-out use of the live vaccine after October 2017. The results were remarkable: those who received the recombinant vaccine exhibited a significantly lower risk of dementia over the following six years, boasting 17% more time free from the diagnosis. Specifically, this group enjoyed an average of 164 additional days without a dementia diagnosis compared to those receiving the older vaccine.

Eligibility Expanding – A New Age of Protection

Currently, the Shingrix recombinant vaccine is offered to adults aged 65-80 through the NHS, along with individuals over 50 with severely compromised immune systems. Starting in September 2025, this eligibility will expand to include immunocompromised individuals aged 18 and above.

A Glimmer of Hope, But Caution Required

While these findings are promising, researchers urge caution. The shingles vaccine should not be mistaken for a definitive solution against dementia. Nevertheless, this cognitive protection presents a compelling argument for older adults to get vaccinated, as recommended by health authorities. With around 1,674,000 projected cases of dementia among those over 60 in the UK by 2025, and predictions suggesting a rise to 1,971,000 by 2032, an increase in shingles vaccine uptake could potentially alter this trajectory and reduce dementia cases over time.